Gene Editing Company Joins Forces to Advance Gene Therapy

Gene Editing Company Joins Forces to Advance Gene Therapy

By: Tomas Ronolski - News

Monday, April 1, 2024

One of the biggest hurdles in gene therapy is safely and efficiently delivering the editing tools into the target cells. Breakthroughs have come with limitations — but this collaboration looks to address these challenges. 

Gene editing company SOHM, Inc. (SHMN) is teaming up with Coastar Therapeutics, a leader in drug delivery systems, to revolutionize gene therapy. This collaboration leverages SOHM's ABBIE (A Binding Based Integrase Enzyme) technology, a powerful tool for precise genome editing, with Coastar's innovative drug delivery system derived from red blood cell membranes.

Coastar’s red blood cell membrane-derived carriers hold immense potential. These biocompatible carriers can evade the immune system and effectively deliver therapeutic cargo directly into cells. By combining these technologies, SOHM and Coastar aim to create a more precise and efficient gene editing approach.

This collaboration has the potential to unlock new possibilities in gene therapy. With a more targeted and effective delivery system, SOHM's ABBIE technology could pave the way for treatments for a wider range of genetic diseases.


Copyright © 2024 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Canadian Inflation Moves Up as Expected But Easing Underlying Pressures Boost Hopes of June Rate Cut
Micro Cap Has Strong Reaction To Share Repurchase Program
Shares Up as Firm Launches First Short Spot Bitcoin ETP in the Nordics
Most Popular
FREE Newsletter Favorites

Back to Top